RecruitingNCT06765850

The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.

Measurement of the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography.

Sponsor

Technische Universität Dresden

Enrollment

3,000 participants

Start Date

Jul 4, 2022

Study Type

OBSERVATIONAL

Conditions

Melanoma of Skin

Summary

Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage. The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a technique called NMR spectroscopy to analyze metabolites (small molecules) in the blood of melanoma patients. The goal is to better understand the biology of melanoma and potentially find new markers that could help with diagnosis or treatment in the future. This is an observational study — no experimental treatment is given. **You may be eligible if...** - You have a current or past diagnosis of melanoma (any stage) - You are currently receiving treatment for melanoma or are in follow-up care at the Skin Cancer Centre at Dresden University Hospital **You may NOT be eligible if...** - You choose not to participate - You do not have the mental capacity to give informed consent Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility